drugset / Trial / NCT05837845
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
Phase 2
Recruiting
30 enrolled
Patricia Suppes
Stanford University · collabSteven & Alexandra Cohen Foundation · collabVA Palo Alto Health Care System · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
In partnership with the Veterans Affairs (VA) Palo Alto Health Care System and Stanford University, this study aims to evaluate clinical outcomes, assess implementation feasibility, and health economics of MDMA-assisted Cognitive Processing Therapy (MDMA-aCPT) in the treatment of posttraumatic stress disorder (PTSD). Through a randomized comparison of MDMA-aCPT versus Cognitive Processing Therapy (CPT), a VA gold standard treatment for PTSD, the proposed study will set the stage for understanding the potential use and application of MDMA-aCPT for PTSD within the VA system.
Timeline
- Start
- 2025-02-10
- Primary completion
- 2027-05
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 3,4-methylenedioxymethamphetamine | Unknown | 80 mg | — |
| Subject | 3,4-methylenedioxymethamphetamine | Unknown | 120 mg | — |